Electronic Resource
Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients
| العنوان: | Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients |
|---|---|
| المؤلفون: | Beije, N. (Nick), Sieuwerts, A.M. (Anieta), Kraan, J. (Jaco), Van, N.M. (Ngoc M.), Onstenk, W. (Wendy), Vitale, S.R. (Silvia R.), van der Vlugt-Daane, M. (Michelle), Dirix, L.Y. (Luc), Brouwer, A. (Anja), Hamberg, A.P. (Paul), Jongh, F.E. (Felix) de, Jager, A. (Agnes), Seynaeve, C.M. (Caroline), Jansen, M.P.H.M. (Maurice), Foekens, J.A. (John), Martens, J.W.M. (John), Sleijfer, S. (Stefan) |
| بيانات النشر: | 2017-01-01 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may yield endocrine resistance in metastatic breast cancer (MBC) patients. These putative endocrine resistance markers are likely to emerge during treatment, and therefore, its detection in liquid biopsies, such as circulating tumor cells (CTCs) and cell-free DNA (cfDNA), is of great interest. This research aimed to determine whether ESR1 mutations and splice variants occur more frequently in CTCs of MBC patients progressing on endocrine treatment. In addition, the presence of ESR1 mutations was evaluated in matched cfDNA and compared to CTCs. CellSearch-enriched CTC fractions (≥5/7.5 mL) of two MBC cohorts were evaluated, namely (a) patients starting first-line endocrine therapy (n = 43, baseline cohort) and (b) patients progressing on any line of endocrine therapy (n = 40, progressing cohort). ESR1 hotspot mutations (D538G and Y537S/N/C) were evaluated in CTC-enriched DNA using digital PCR and compared with matched cfDNA (n = 18 baseline cohort; n = 26 progressing cohort). Expression of ESR1 full-length and 4 of its splice variants ((increment)5, (increment)7, 36 kDa, and 46 kDa) was evaluated in CTC-enriched mRNA. It was observed that in the CTCs, the ESR1 mutations were not enriched in the progressing cohort (8%), when compared with the baseline cohort (5%) (P = 0.66). In the cfDNA, however, ESR1 mutations were more prevalent in the progressing cohort (42%) than in the baseline cohort (11%) (P = 0.04). Three of the same mutations were observed in both CTCs and cfDNA, 1 mutation in CTCs only, and 11 in cfDNA only. Only the (increment)5 ESR1 splice variant was CTC-specific expressed, but was not enriched in the progressing cohort. In conclusion, sensitivity for detecting ESR1 mutations in CTC-enriched fractions was lower than for cfDNA. ESR1 mutations detected in cfDNA, rarely present at the start of first-line endocrine therapy, were enriched at progression, strongly suggesting a role in conf |
| مصطلحات الفهرس: | Cell-free DNA, Circulating tumor cells, Endocrine resistance, ESR1 mutations, info:eu-repo/semantics/article |
| DOI: | 10.1002.1878-0261.12147 |
| URL: | |
| الاتاحة: | Open access content. Open access content info:eu-repo/semantics/openAccess |
| ملاحظة: | application/pdf Molecular Oncology English |
| Other Numbers: | QGQ oai:repub.eur.nl:102992 doi:10.1002/1878-0261.12147 urn:hdl:1765/102992 1022217484 |
| المصدر المساهم: | ERASMUS UNIVERSITEIT ROTTERDAM From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1022217484 |
| قاعدة البيانات: | OAIster |
| DOI: | 10.1002.1878-0261.12147 |
|---|